Pacira BioSciences SVP Lauren Riker sells $217,920 in stock

On October 8, 2026, Senior Vice President of Finance Lauren Riker at Pacira BioSciences sold 6,000 shares of the company's common stock for a total value of $217,920. The shares were sold at $36.32 per share, slightly below the stock's 52-week high of $36.46. This investment move came as the stock surged 44% in just a week, yet the company remains undervalued according to Fair Value analysis.

Just before selling, Riker had bought 6,000 shares through stock options at $32.35 per share, investing $194,100. The transactions followed a Rule 10b5-1 trading plan adopted on March 12, 2026. Ms. Riker now directly owns 62,284.242 shares of Pacira BioSciences common stock. Meanwhile, Pacira reported a 6% increase in its second-quarter revenue to $192.4 million, beating expectations of $191.06 million.

This growth was driven by the expansion of main products and a major payer coverage win. Viatris acquired Pacira Pharmaceuticals for $1.65 billion, prompting Jefferies to downgrade Pacira's stock rating to 'Hold' with a price target of $36.00. Despite this, Oppenheimer gave Pacira an 'Outperform' rating with a price target of $32.00, citing the strong commercial phase of Exparel, Pacira's product.